Does Aetna (CVS Health) Cover Crestor (Rosuvastatin)?

How Aetna (CVS Health) Classifies Crestor on Its Formulary

Aetna (CVS Health) places brand-name Crestor on a non-preferred brand tier, most commonly Tier 3 or Tier 4, on the majority of its commercial PPO and HMO products. Generic rosuvastatin usually sits at Tier 1 or Tier 2. The cost difference is significant: a 30-day supply of brand Crestor can carry a copay of $60 to $120 at non-preferred tiers, compared with $10 to $20 for the generic on a preferred generic tier.

Aetna's drug formulary is managed in partnership with CVS Caremark, the pharmacy benefit manager CVS Health operates. Because CVS Caremark has negotiated deep rebates on several generic statins, brand Crestor rarely earns preferred status on any commercial Aetna plan as of 2025. The CVS Caremark formulary management principles prioritize cost-effective therapeutic equivalents, which is why generic rosuvastatin is almost always the preferred route.

The FDA approved rosuvastatin calcium (Crestor) in August 2003 for hyperlipidemia, mixed dyslipidemia, and primary prevention of cardiovascular disease. The FDA-approved prescribing information confirms indicated doses range from 5 mg to 40 mg daily, with 10 mg and 20 mg being the most commonly prescribed starting doses. Generic rosuvastatin became available in the United States in 2016 following patent expiration, and its entry drove brand Crestor off preferred formulary positions across nearly all major payers. [1]

Each Aetna plan document, formally called the Summary of Benefits and Coverage (SBC), lists the exact tier assignment and cost-sharing amounts. Patients should pull their specific SBC from the Aetna member portal at aetna.com before assuming any tier applies to their plan.

Prior Authorization Criteria Aetna Uses for Crestor

Aetna requires prior authorization for brand-name Crestor on most commercial plans, and the clinical criteria follow a predictable pattern aligned with ACC/AHA cholesterol guidelines. Generic rosuvastatin typically does not require PA on standard commercial plans, which is the single fastest path to covered therapy.

For brand Crestor specifically, Aetna's PA criteria generally require the prescriber to document: (1) a confirmed diagnosis of hyperlipidemia, heterozygous familial hypercholesterolemia (HeFH), or established ASCVD; (2) a clinical reason why the generic formulation is inadequate, such as a documented intolerance to a specific excipient present only in the generic; and (3) in most cases, evidence that the patient has already tried at least one alternative covered statin. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol sets the clinical framework most payers reference when writing these criteria. [2]

The guideline states directly: "For patients with clinical ASCVD, reduce LDL-C with high-intensity statin therapy or maximally tolerated statin therapy." [2] Aetna's PA forms typically ask the prescriber to confirm that the requested drug aligns with this risk-stratification approach.

PA requests for brand Crestor go through CVS Caremark's clinical authorization team. Turnaround for a standard (non-urgent) PA request is up to 72 hours under Aetna's member rights policies. Urgent requests tied to a clinical need must receive a decision within 24 hours. Submitting incomplete documentation, such as missing recent lipid panel results or no documentation of prior statin trials, is the most common reason for initial denial.

Prescribers can submit PA requests via the CVS Caremark provider portal, by fax using Aetna's PA request form, or through electronic prior authorization (ePA) integrated into major EHR platforms. Sending a recent lipid panel (dated within 12 months), the patient's full medication history, and any documented intolerance notes in the initial submission reduces the likelihood of a denial. [3]

Step Therapy Requirements: Which Statins Aetna Tries First

Step therapy means a plan requires a patient to try and fail at least one preferred alternative before the requested drug is approved. Aetna applies step therapy to brand Crestor on most commercial formularies, and the required first-step drugs are typically preferred generic statins.

The most commonly required step-therapy agents under Aetna's statin policy are atorvastatin (generic Lipitor) and simvastatin, both of which sit at Tier 1 on nearly all Aetna formularies. Pravastatin and lovastatin appear as acceptable alternatives on some plan variants. Generic rosuvastatin itself may satisfy the step-therapy requirement on plans where it is classified as a preferred generic, meaning a patient who has already been on generic rosuvastatin at an adequate dose may qualify for brand Crestor approval if a documented clinical reason justifies the brand.

Step therapy exemptions exist under state law in several states. As of 2024, more than 30 states have enacted step therapy override laws that require health plans to grant exceptions when a patient has already tried the required alternative and it was ineffective or caused an adverse reaction, when the required drug is contraindicated, or when the patient is stable on the requested drug. The National Conference of State Legislatures tracks these statutes, and patients in qualifying states may file a step therapy override request alongside or instead of a standard PA. [4]

Clinically, the evidence supporting rosuvastatin at high intensity (20 to 40 mg daily) is well-established. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% versus placebo (hazard ratio 0.56 to 95% CI 0.46 to 0.69, P<0.001) in patients with elevated high-sensitivity CRP and LDL-C below 130 mg/dL. [5] That magnitude of LDL reduction, approximately 50% from baseline, is difficult to replicate with atorvastatin 10 mg or simvastatin 20 mg at step-therapy starting doses, which gives prescribers a legitimate clinical rationale to document when arguing for rosuvastatin specifically.

The ACC/AHA 2018 guidelines define high-intensity statin therapy as daily doses that lower LDL-C by approximately 50% or more, a category that includes rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg. [2] If a patient's prescriber has tried atorvastatin 40 mg or 80 mg and the patient cannot tolerate it or has not reached LDL-C goal, that failure provides the clearest step-therapy override rationale for brand or generic rosuvastatin.

How to Appeal an Aetna Denial of Crestor Coverage

A denial is not final. Aetna's internal and external appeal process follows a defined sequence, and a well-documented appeal overturns denials more often than a bare submission does.

Step 1: First-level internal appeal. After receiving a denial, the member or prescriber has 180 days to file a first-level internal appeal in writing. The appeal should include the original denial letter, an updated letter of medical necessity from the prescriber, documentation of any prior statin trials and their outcomes, recent lab values (lipid panel, LFTs if relevant), and a direct reference to the applicable ACC/AHA guideline recommendation. Aetna must respond within 30 days for pre-service appeals and 60 days for post-service appeals under federal regulations governing employer-sponsored plans. [6]

Step 2: Second-level internal appeal. If the first-level appeal is denied, Aetna offers a voluntary second-level review, typically conducted by a different clinical reviewer or a physician reviewer in the relevant specialty. This step is optional but can strengthen a case before external review.

Step 3: External independent review. Federal law under the Affordable Care Act requires Aetna to offer an independent external review for any final adverse benefit determination involving medical judgment. The external reviewer is an Independent Review Organization (IRO) accredited by URAC or a comparable body. IRO decisions are binding on Aetna. [6] The HHS guidance on external review processes outlines member rights in detail.

Step 4: State insurance department complaint. Members may file a complaint with their state insurance commissioner simultaneously or after exhausting internal appeals. This step is separate from the IRO process and can trigger an independent investigation of Aetna's denial pattern for a given drug class.

When writing a letter of medical necessity for a Crestor appeal, prescribers should cite the JUPITER results directly, reference the patient's specific LDL-C goal under ACC/AHA risk stratification, and document any adverse effects from the step-therapy statin with specificity (dates, doses, symptoms, any relevant labs). [5] A letter that says "patient could not tolerate atorvastatin" is weaker than one that says "patient developed myalgia at atorvastatin 20 mg confirmed by CK elevation to 3x ULN on 2024-09-15, with symptom resolution upon discontinuation." Specificity wins appeals.

Crestor for FH and High-Risk ASCVD: Does Aetna Apply Different Rules?

Patients with familial hypercholesterolemia or established high-risk ASCVD may face a faster PA pathway than standard hyperlipidemia patients, though the documentation requirements are heavier.

Heterozygous FH affects approximately 1 in 250 people in the United States, according to data from the FH Foundation cited in NCBI literature. [7] These patients often require high-intensity statin doses from the outset, and step therapy through low-intensity statins may be clinically inappropriate. Aetna's PA criteria for FH typically accept a documented genetic mutation (LDLR, APOB, or PCSK9 pathogenic variant) or a clinical FH diagnosis using the Dutch Lipid Clinic Network or Simon Broome criteria as a justification to skip or abbreviate step therapy.

For secondary prevention patients who have had a myocardial infarction, stroke, or coronary revascularization, the ACC/AHA guideline gives a Class I recommendation for high-intensity statin therapy, and Aetna's clinical criteria generally align with that standard. [2] Prescribers documenting a post-MI patient or a patient with symptomatic peripheral artery disease should explicitly cite the secondary prevention indication, since Aetna's PA reviewers are more likely to approve brand-name or high-dose rosuvastatin when the cardiovascular risk tier is clearly established.

Pediatric FH is also an approved indication for rosuvastatin. The FDA label permits use of rosuvastatin 5 to 20 mg in patients aged 8 to 17 years with HeFH. [1] PA for pediatric patients typically requires a pediatric lipid specialist note and documented LDL-C levels meeting FH diagnostic thresholds.

Manufacturer Savings Cards and Patient Assistance

AstraZeneca offers a savings card for brand Crestor, but it carries a critical restriction that affects most Aetna members.

Manufacturer copay cards are not valid for use by patients enrolled in any federal healthcare program, including Medicare, Medicaid, TRICARE, or any plan where the drug cost is reimbursed even in part by a federal program. For commercial Aetna members who are not enrolled in any government program, the AstraZeneca savings card may reduce the out-of-pocket cost of brand Crestor. However, since 2022 several states have enacted copay accumulator laws, and Aetna has applied accumulator adjustment programs (AAPs) on many of its commercial plans, meaning that manufacturer card payments may not count toward the patient's annual deductible or out-of-pocket maximum. [8]

The practical result: a patient using a manufacturer card for brand Crestor on an Aetna plan with an AAP will pay lower monthly copays but may face a larger true out-of-pocket burden at year end because the card payments did not reduce their deductible. Generic rosuvastatin carries no such complexity. At a GoodRx cash price of approximately $15 for 30 tablets of rosuvastatin 20 mg, many patients save more by abandoning the brand and paying cash for the generic than by fighting for brand coverage.

The HealthRX clinical team suggests a simple decision framework for patients whose Aetna plan denies brand Crestor. First, confirm whether the prescriber is willing to prescribe generic rosuvastatin at the therapeutically equivalent dose. If so, switching to the generic resolves the coverage problem immediately and typically costs $10 to $20 per month with insurance. If the prescriber has a specific clinical reason to stay with brand Crestor (a documented formulation-specific tolerability issue, for example), then proceed with the PA and appeal pathway described above. The decision to fight for brand coverage makes sense only when generic rosuvastatin has genuinely failed or is contraindicated.

What the Clinical Evidence Says About Rosuvastatin Efficacy

The insurance coverage fight is worth understanding in a clinical context, because the evidence supporting rosuvastatin at high intensity is among the strongest in preventive cardiology.

JUPITER (N=17,802, median follow-up 1.9 years) showed rosuvastatin 20 mg daily reduced the primary composite endpoint of MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56, P<0.001) in apparently healthy adults with LDL-C below 130 mg/dL. [5] The trial was stopped early by the data safety monitoring board because the benefit was so clear. Mean LDL-C fell from 108 mg/dL to 55 mg/dL in the rosuvastatin arm, a 49% reduction. [5]

A 2019 Cochrane review of statin therapy for primary prevention of cardiovascular disease (N=116,477 across 18 trials) confirmed that statins reduce all-cause mortality (OR 0.86 to 95% CI 0.79 to 0.94) and major coronary events (OR 0.70 to 95% CI 0.61 to 0.81) without increasing the risk of serious adverse events at standard doses. [9] Rosuvastatin is one of three high-intensity statins included in that analysis.

The 2022 ACC/AHA guideline update on coronary artery disease reaffirms high-intensity statin therapy as a Class I, Level A recommendation for patients aged 40 to 75 with LDL-C of 70 mg/dL or higher and a 10-year ASCVD risk of 7.5% or greater. [10] Rosuvastatin 20 to 40 mg meets the high-intensity threshold and remains one of two statins (alongside atorvastatin 40 to 80 mg) explicitly named in that recommendation. Prescribers should cite this classification number, Class I Level A, in PA submissions to strengthen the medical necessity argument.

At the approved maximum dose of 40 mg daily, rosuvastatin reduces LDL-C by approximately 55 to 60% from baseline, which outperforms atorvastatin 80 mg (approximately 50% reduction) in head-to-head comparative analyses, though both agents achieve target LDL-C in most patients when titrated properly. [1]

Checking Your Specific Aetna Plan Before Submitting a PA

No two Aetna plans are identical. Tier assignments, PA criteria, and step-therapy lists can differ between a large employer self-funded plan, a fully insured small-group plan, and an Aetna Medicare Advantage plan, even within the same calendar year.

The fastest way to check your specific plan's coverage is to log in to aetna.com, manage to the formulary search tool, and enter the NDC or drug name "rosuvastatin" or "Crestor." The tool returns the current tier, any PA or step-therapy flags, and the estimated cost-sharing based on your plan's benefit design. Alternatively, the CVS Caremark member portal (caremark.com) provides the same data if your pharmacy benefits are managed there.

Calling Aetna member services at the number on the back of the insurance card and asking specifically about rosuvastatin prior authorization criteria takes approximately 10 minutes and gives real-time information. Ask the representative to note the call in the member's file, and request the specific clinical criteria document that Aetna applies to the PA decision. Under federal transparency requirements, Aetna must provide this criteria document upon request. [6]

For patients covered by an employer self-funded plan, the plan sponsor, typically the employer's HR department, holds authority over benefit design independent of Aetna's standard formulary. Some employers negotiate custom formularies that place brand Crestor at a lower tier or remove PA requirements entirely. Checking with HR before assuming standard Aetna formulary rules apply may save weeks of PA paperwork.

Aetna Medicare Advantage plans follow CMS formulary requirements, and brand Crestor's placement on Medicare Part D formularies is governed by a separate CMS review process. Generic rosuvastatin is generally on the $0 or low-cost-sharing tier on Medicare Part D plans following the Inflation Reduction Act's $35 insulin cap model for high-value generics.